VKH
FATE icon

Virtu KCG Holdings’s Fate Therapeutics FATE Stock Holding History

Virtu KCG Holdings’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-24,480
Closed -$111K – 3046
2017
Q1 		$111K Buy
24,480
+1,764
+8% +$6.45K ﹤0.01% 2653
2016
Q4 		$57K Buy
22,716
+9,368
+70% +$25.1K ﹤0.01% 3062
2016
Q3 		$42K Buy
+13,348
New +$32.4K ﹤0.01% 2820
2016
Q1 		– Sell
-15,057
Closed -$51K – 3066
2015
Q4 		$51K Buy
+15,057
New +$63.3K ﹤0.01% 3154

Other funds holding FATE

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Virtu KCG Holdings's FATE Position: Q2 2017 in Review

Virtu KCG Holdings sold out of Fate Therapeutics (FATE) in Q2 2017, closing a stake of 24,480 shares — an estimated $111K sold.

Virtu KCG Holdings first reported a position in FATE in Q4 2015 and held it in 4 quarters. The position peaked at $111K in Q1 2017. 60 funds tracked by Wall St. Rank hold FATE as of Q2 2017.

  • Virtu KCG Holdings reported no remaining Fate Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Virtu KCG Holdings sold 24,480 Fate Therapeutics shares in Q2 2017, an estimated $111K.
  • Virtu KCG Holdings first reported a position in Fate Therapeutics in Q4 2015 and held it in 4 quarters.
  • Virtu KCG Holdings's Fate Therapeutics position peaked at $111K in Q1 2017.
  • 60 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.